<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2975">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04775017</url>
  </required_header>
  <id_info>
    <org_study_id>COVID-19-Delirium</org_study_id>
    <nct_id>NCT04775017</nct_id>
  </id_info>
  <brief_title>Delirium in Covid-19: Germany-wide Covid-19 Intensive Register</brief_title>
  <official_title>Delirium in Covid-19: Germany-wide Covid-19 Intensive Register</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The global pandemic caused by the SARS-CoV-2 virus is confronting the German health system&#xD;
      with a novel pathogen. This means that a timely evaluation of all available results is&#xD;
      required. In the field of intensive care in particular, there are significant gaps in&#xD;
      knowledge, particularly with regard to delirium. In this respect, this study also serves&#xD;
      directly to investigate the pathways of delirium outcome in COVID-19 patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of delirium</measure>
    <time_frame>01.01.2020 - 31.07.2020</time_frame>
    <description>Delirium is measured by validated screening scores.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Risk factors for severe COVID-19</measure>
    <time_frame>01.01.2020 - 31.07.2020</time_frame>
    <description>Risk factors are defined according to actual literature e.g. obesity, diabetes or hypertension.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient characteristics</measure>
    <time_frame>01.01.2020 - 31.07.2020</time_frame>
    <description>Patient characteristics at hospital admission e.g. score level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood gas analysis</measure>
    <time_frame>01.01.2020-31.07.2020</time_frame>
    <description>Monitoring of blood gas analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Enteral nutrition</measure>
    <time_frame>01.01.2020-31.07.2020</time_frame>
    <description>Monitoring of enteral nutrition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parenteral nutrition</measure>
    <time_frame>01.01.2020-31.07.2020</time_frame>
    <description>Monitoring of parenteral nutrition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum albumin</measure>
    <time_frame>01.01.2020-31.07.2020</time_frame>
    <description>Monitoring of serum albumin level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total protein</measure>
    <time_frame>01.01.2020-31.07.2020</time_frame>
    <description>Monitoring of total protein level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phosphate</measure>
    <time_frame>01.01.2020-31.07.2020</time_frame>
    <description>Monitoring of phosphate levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglyceride</measure>
    <time_frame>01.01.2020-31.07.2020</time_frame>
    <description>Monitoring of triglyceride levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caloric intake</measure>
    <time_frame>01.01.2020 - 31.07.2020</time_frame>
    <description>Caloric intake is measured by total daily energy supply.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory setting</measure>
    <time_frame>01.01.2020 - 31.07.2020</time_frame>
    <description>Respiratory factors are measured respiratory setting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory laboratory parameter 1</measure>
    <time_frame>01.01.2020 - 31.07.2020</time_frame>
    <description>Monitoring of interleukine level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory laboratory parameter 2</measure>
    <time_frame>01.01.2020 - 31.07.2020</time_frame>
    <description>Monitoring of cytokine level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory laboratory parameter 3</measure>
    <time_frame>01.01.2020 - 31.07.2020</time_frame>
    <description>Monitoring of big immune status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory laboratory parameter 4</measure>
    <time_frame>01.01.2020 - 31.07.2020</time_frame>
    <description>Monitoring of t-cell population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxic-drug factors</measure>
    <time_frame>01.01.2020 - 31.07.2020</time_frame>
    <description>Toxic-drug factors are measured by concomitant medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sociodemographic factors</measure>
    <time_frame>01.01.2020 - 31.07.2020</time_frame>
    <description>Sociodemographic factors are measured by Audit, Fagerström, occupation, age, gender, cognitive status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breathing hours</measure>
    <time_frame>01.01.2020 - 31.07.2020</time_frame>
    <description>Breathing hours are measured by non-invasive and invasive ventilation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of intensive care unit stay</measure>
    <time_frame>01.01.2020 - 31.07.2020</time_frame>
    <description>Length of intensive care unit stay is measured in days of stay in the intensive care unit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>01.01.2020 - 31.07.2020</time_frame>
    <description>Length of hospital stay is measured in days of stay in hospital.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>01.01.2020 - 31.07.2020</time_frame>
    <description>Adverse Events defined by thromboembolic events, nosocomial infections, septic shock, acute renal failure, heart attack, post-intensive care syndrome and death are recorded until hospital discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post Intensivecare Unit Syndrome (PICS)</measure>
    <time_frame>01.01.2020 - 31.01.2021</time_frame>
    <description>Post Intensive Care Unit Syndrome (PICS) is measured by a validated battery (composite endpoint).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital mortality</measure>
    <time_frame>01.01.2020 - 31.07.2020</time_frame>
    <description>Mortality is measured in the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>01.01.2020 - 31.01.2021</time_frame>
    <description>Mortality is measured until 180 days</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Intensive Care Unit Delirium</condition>
  <condition>Covid19</condition>
  <condition>Post Intensive Care Unit Syndrome</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who have COVID-19 and have been treated in an intensive care unit of Charité&#xD;
        Universitätsmedizin and whose therapy has already been completed on 31.07.2020.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All patients with SARS-CoV-2 positive Covid-19 disease&#xD;
&#xD;
          -  Age≥18 years&#xD;
&#xD;
          -  Proven by positive PCR tests from nasal/ throat swabs as well as samples from the deep&#xD;
             respiratory tract.&#xD;
&#xD;
          -  Period 01.01.2020 to 31.07.2020&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  NONE&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudia Spies, MD, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Charité - Universitäsmedizin Berlin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claudia Spies, MD, Prof.</last_name>
    <phone>+49 30 450 551102</phone>
    <email>claudia.spies@charite.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Anesthesiology and Operative Intensive Care Medicine Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Spies, MD, Prof.</last_name>
      <phone>+49 30 450 55 11 02</phone>
      <email>claudia.spies@charite.de</email>
    </contact>
    <investigator>
      <last_name>Claudia Spies, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreas Edel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 21, 2021</study_first_submitted>
  <study_first_submitted_qc>February 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>February 26, 2021</last_update_submitted>
  <last_update_submitted_qc>February 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Claudia Spies</investigator_full_name>
    <investigator_title>Head of the Department of Anesthesiology and Operative Intensive Care Medicine (CCM/CVK)</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

